Protalix BioTherapeutics (PLX) Interest Expenses (2011 - 2025)

Protalix BioTherapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $875000.0 for Q4 2025.

• On a quarterly basis, Interest Expenses rose 2034.15% year-over-year to $875000.0 in Q4 2025; TTM through Mar 2026 was $1.3 million, a 58.76% increase from a year earlier, with the FY2025 full-year figure at $50.4 million, down 0.59% from the prior year.
• Interest Expenses advanced to $875000.0 in Q4 2025 per PLX's latest filing, from $457000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $2.4 million in Q3 2021 and bottomed at $6000.0 in Q1 2025.
• The 5-year median for Interest Expenses is $639000.0 (2022), against an average of $849473.7.
• Biggest YoY gain for Interest Expenses was 2034.15% in 2025; the steepest drop was 99.22% in 2025.
• Year by year, Interest Expenses stood at $122000.0 in 2021, then surged by 432.79% to $650000.0 in 2022, then sank by 32.77% to $437000.0 in 2023, then sank by 90.62% to $41000.0 in 2024, then soared by 2034.15% to $875000.0 in 2025.
• Per Business Quant, the three latest PLX Interest Expenses figures stand at $875000.0 (Q4 2025), $457000.0 (Q3 2025), and $6000.0 (Q1 2025).